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Abstract
Transglutaminase 2 (TG2) is a multifunctional mammalian protein with transamidase and signaling properties. Using
selective TG2 inhibitors and tagged nucleophilic amine substrates, we show that the majority of extracellular TG2 is inactive
under normal physiological conditions in cell culture and in vivo. However, abundant TG2 activity was detected around the
wound in a standard cultured fibroblast scratch assay. To demonstrate wounding-induced activation of TG2 in vivo, the toll-
like receptor 3 ligand, polyinosinic-polycytidylic acid (poly(I:C)), was injected in mice to trigger small intestinal injury.
Although no TG2 activity was detected in vehicle-treated mice, acute poly(I:C) injury resulted in rapid TG2 activation in the
small intestinal mucosa. Our findings provide a new basis for understanding the role of TG2 in physiology and disease.
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Introduction
Transglutaminase 2 (TG2, tissue transglutaminase, transgluta-
minase C, Gah) is a multifunctional protein found in most
mammalian tissues capable of enzymatic, cell adhesion, cell
signaling, and G-protein activities [1–4]. A ubiquitous protein, its
function is presumably dictated by its cellular localization,
interaction with other proteins and binding to cofactors [1–3].
In the presence of calcium and the absence of GTP or GDP, TG2
can act as an enzyme capable of post-translationally modifying
proteins through transamidation or deamidation. As a transami-
dase, TG2 catalyzes the formation of an isopeptide bond
(intermolecular e-(c-glutamyl) lysine crosslink) between a selected
glutamine residue on one substrate and a lysine residue on a
second substrate. Alternatively, certain small molecule amines can
also be attached onto glutamine side-chains of proteins by TG2. In
the absence of adequate concentrations of any suitable amine
substrate, TG2 deamidates the targeted glutamine side chain,
resulting in its conversion to glutamate [2,3,5].
The enzymatic activity of TG2 is of pharmacological interest
because it is believed to contribute to the pathogenesis of diseases
such as celiac sprue [6], neurodegenerative disorders [7], type 2
diabetes [8], and certain cancers [9–11]. For example, in celiac
sprue gluten peptides resistant to proteolysis by gastro-pancreatic
proteases [12] are deamidated by TG2 in the small intestine of
patients [13]. The negative charge introduced by peptide
deamidation increases the affinity of these gluten peptides for
the disease associated HLA-DQ2 protein [14] thereby triggering
an inflammatory T cell response that ultimately leads to the
destruction of small intestinal architecture [15]. Furthermore, an
anti-TG2 antibody response is mounted in patients on a gluten-
containing diet but is silenced when gluten is excluded from the
diet suggesting the close interaction of gluten peptides with TG2
[15].
Due to the therapeutic potential of inhibiting TG2 enzyme
activity, many classes of TG2 irreversible inhibitors that form
stable covalent bonds with the TG2 active site cysteine have been
synthesized [16,17]. Among these inhibitors, 3-bromo-4,5-dihy-
droisoxazoles are among the most well-studied from a structure-
activity and biological viewpoint [11,18–20]. These inhibitors are
also useful chemical probes for assessing the enzymatic activity of
TG2 in biological systems. Most previous attempts to study TG2
activity in mammalian tissues involved tissue homogenization and
lysis, followed by a crosslinking activity assay of the lysate using
buffers with millimolar levels of calcium [21]. Not only does this
method result in a loss of the tissue localization of TG2, but the
presence of high calcium concentrations in the buffer leads to
activation of enzymatically latent TG2 (vide infra). Therefore,
although this method is appropriate for quantifying the abundance
of TG2 protein in tissue samples, it does not report on TG2 enzyme
activity in vivo. Alternate methods for assaying in situ TG2 activity
involve the incubation of histological sections with labeled amine
substrates such as monodansyl cadaverine or 5-biotinamidopenty-
lamine [22,23]. Again, these assays entail incubation of tissue
samples in calcium buffers and are often preceded by fixation or
comparable perturbation of the tissue.
In this study, we probed the activity of TG2 in intact biological
systems. A variety of active site-directed inhibitors and tagged
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cein cadaverine, and
14C-putrescine) of TG2 were synthesized and
evaluated. While previous studies suggest the enzymatic latency of
intracellular TG2 in cell culture [24,25], our data suggest that the
majority of extracellular TG2 is also inactive despite an
environment conducive to enzyme activation. On the other hand,
TG2 could be enzymatically activated and inhibited in a standard
cultured fibroblast wounding model. In an attempt to demonstrate
wounding-induced activation of latent TG2 in vivo, the poly-
inosinic-polycytidylic acid (poly(I:C)) small intestinal injury model
[26] was used to examine in vivo TG2 activity. In accord with the
fibroblast culture assay and consistent with a role for active TG2
following tissue injury, small intestinal TG2 was enzymatically
activated in the acute poly(I:C) injury model. Our results provide
a mechanistic framework to understand the catalytic and
non-catalytic functions of mammalian TG2 in physiology and
disease.
Results
Cellular TG2 is not inhibited by dihydroisoxazole
inhibitors
In order to determine if 3-bromo-4,5-dihydroisoxazole irrevers-
ible inhibitors are able to covalently bind cellular TG2, 100 mM
compound 1 was diluted into culture media and incubated at 37uC
for one hour with WI-38 fibroblasts and MDA-MB-231 cells, two
cell lines previously shown to express abundant TG2 protein [27–
30]. To evaluate the level of inhibition of TG2 activity, the cells
were subsequently washed, lysed by sonication, divided into four
aliquots of lysate (see below), incubated for 30 minutes at ambient
temperature, and diluted into a calcium-rich activity assay buffer
to measure TG2 catalyzed putrescine incorporation into dimethyl
casein.
The first aliquot contained vehicle (1% DMSO) and was
analyzed to determine the level of TG2 inhibition that occurred
during cell culture. As shown in Figure 1B, no significant
inhibition was observed indicating the enzymatic latency of the
majority of cellular TG2. The second aliquot of lysate, into which
100 mM inhibitor 1 in 1% DMSO was added, also did not result in
inhibition of TG2 activity implying that inhibitor 1 was unable to
irreversibly bind TG2 after cell lysis. The third aliquot was a control
that contained 1% DMSO with 5 mM CaCl2. The level of TG2
activity decreased slightly in these samples possibly due residual
inhibitor 1 left over from incomplete washing of the cells and/or the
increased susceptibility of TG2 to proteolysis in the presence of
calcium [31,32]. The fourth aliquot of cell lysate received 100 mM
inhibitor 1 and 5 mM CaCl2 in 1% DMSO and resulted in nearly
complete inhibition of TG2 activity (Figure 1B). In summary, these
results indicate that (i) the majority of cellular TG2 cannot be
inhibited in intact cells; (ii) dihydroisoxazole inhibitor 1 potently
inhibits cell lysate TG2 activity in the presence of calcium; and (iii)
calcium in the putrescine incorporation assay buffer results in
activation of previously latent TG2, suggesting that this assay is not a
reliable indicator of in vivo TG2 activity. Rather, it is useful in
assessing total TG2 protein content or total potential TG2 activity
(which we will hereafter refer to as ‘‘ex vivo TG2 activity’’).
The majority of small intestinal and liver TG2 cannot be
inhibited under normal physiological conditions
Because TG2 is highly expressed in the liver and small intestine,
we selected these two organs as targets for TG2 inhibition by
injecting mice with two previously described active-site directed
irreversible inhibitors from the 3-bromo-4,5-dihydroisoxazole
family of compounds (compounds 2A and 3, Figure 1A) [18,19].
Following animal sacrifice, the organs were harvested, homoge-
nized and assayed for ex vivo TG2 activity (i.e., TG2 activated ex
vivo by calcium in the assay buffer, see Figure 1B) using putrescine
incorporation. Initially we observed a dose-dependent decrease in
ex vivo small intestinal TG2 activity after injecting dihydroisoxazole
inhibitors dissolved in 50% DMSO/PBS although no consistent
inhibition was observed in the liver (liver, Figure 2A; small
intestine, [18]). However, in subsequent experiments, no TG2
inhibition was observed in the small intestine following a thorough
rinse of the small intestinal lumen with PBS prior to tissue
harvesting (Figure 2A). This suggests that the inhibition observed
without intestinal washing was most likely due to TG2 inactivation
by residual amounts of inhibitor that was carried into the tissue
homogenization and lysis steps. Intraperitoneal, intravenous, and
peroral routes of administration were investigated without
observable TG2 inhibition in either organ (Figure 2A and data
Figure 1. Dihydroisoxazole inhibitors do not inhibit TG2 in
intact cells. (A) Chemical structures of the 3-bromo-4,5-dihydroisox-
azole inhibitors used in these studies [18,19]. In some experiments
described herein, the stereoisomers of compound 2A (compounds 2B
and 2C) at the C-5 carbon of the dihydroisoxazole ring (see arrow) were
used. The (S)-isomer (compound 2B) irreversibly inhibits recombinant
human TG2 while the (R)-isomer (compound 2C) does not [19]. (B) WI-
38 fibroblasts and MDA-MB-231 cells were incubated with or without
100 mM inhibitor 1 for 1 hour. Cells were washed with PBS and
detached from the culture plate using 10 mM EDTA in PBS for MDA-MB-
231 cells or using trypsin-EDTA in PBS for WI-38 cells. After lysing the
cells via sonication, the lysate was split into four equal aliquots and
incubated with % 1% DMSO, & 1% DMSO+100 mM 1, & 1%
DMSO+5 mM CaCl2,o r— — % 1% DMSO+100 mM 1+5 mM CaCl2 for
30 minutes at room temperature. TG2-catalyzed putrescine incorpora-
tion into dimethyl casein in a calcium-rich reaction buffer was then used
to quantify the amount of ex vivo TG2 activity in each fraction. Activities
were normalized by total protein concentrations.
doi:10.1371/journal.pone.0001861.g001
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presence of the dihydroisoxazole inhibitors at high (,10 mM)
plasma concentrations ([18], data not shown). Finally, in order to
confirm that the putrescine incorporation assay was indeed
measuring TG2 activity rather than the activity of another
transglutaminase, small intestines were harvested from four wild-
type and four TG2 knockout mice. The average intestinal
transglutaminase activity was 7768 pmol putrescine/min-mg
protein in tissue homogenates from wild-type animals and 462
pmol putrescine/min-mg protein in corresponding samples from
the TG2 knockout animals.
In order to directly access the small intestine, 2.4 mM of
compound 2A was perfused through the small intestine of an
anesthetized rat for 12 minutes. Vehicle perfused sections,
proximal and distal to the section in which the inhibitor was
perfused, were established as controls. Following perfusion, tissue
samples were harvested from each section, frozen in OCT and
subsequently cut to 6 mm thickness. TG2 activity was measured ex
vivo by incubating tissue sections with 5-biotinamidopentylamine
(5-BP) in a calcium-rich buffer (thereby activating most or all of the
uninhibited TG2). No difference was observed in 5-BP abundance
between control- and inhibitor-perfused tissue sections (Figure 2B).
Figure 2. No detectable inhibition of TG2 in the small intestine or liver of mice or rats treated with TG2 inhibitors. (A) Small intestine:
Mice were intraperitoneally (IP) injected with vehicle, 2 mg/kg 3, 6 mg/kg 3, 20 mg/kg 3, or 60 mg/kg 3 or intravenously injected with vehicle or
50 mg/kg 2A before being sacrificed 1 hour post-injection. Small intestinal tissue was flushed with PBS before freezing on dry ice. Liver: Mice were IP
injected with vehicle, 20 mg/kg 2A, or 200 mg/kg 2A and sacrificed 1 hour post-injection. TG2 activity in the tissue lysates was determined using the
putrescine incorporation assay. (Average of two mice. P.0.1 for all doses except 60 mg/kg 3) (B) Ex vivo TG2 activity (orange) was measured using 5-
BP in tissue sections from the small intestine of rats perfused with vehicle or 2.4 mM 2A. Tissue autofluorescence using the 488 nm laser was
collected to help orient and visualize the villous structure of the intestine. (4006) (C) Staining of rat small intestinal tissue for fibronectin (green), TG2
(yellow), and ex vivo TG2 activity (red) revealed nearly perfect overlap of all three stains. (4006)
doi:10.1371/journal.pone.0001861.g002
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BP also did not result in any appreciable signal indicative of in vivo
TG2 activity (data not shown). To verify that this ex vivo TG2
activity assay was indeed specific for TG2 and not another
transglutaminase, both transglutaminase activity and TG2 protein
were visualized in the sectioned tissue, along with an anti-
fibronectin antibody to provide a frame of reference. Nearly
perfect overlap was observed for all three stains (Figure 2C).
Localization, activation and inhibition of TG2 in a tissue
wounding model
Wound healing is an established model system for detecting
TG2 activity [33]. In this model, catalytically active TG2 is
hypothesized to provide mechanical stability to tissues by cross-
linking ECM proteins after a wound has been inflicted. In order to
study the localization and activity status of TG2 in a simplified
cellular model of tissue wounding, WI-38 fibroblast confluent
monolayers were scratched with a small pipette tip and analyzed
for TG2 protein content and activity by fluorescence microscopy.
Although uninjured WI-38 monolayers showed near background
enzyme activity levels despite the presence of extracellular TG2
[27,28], a high density of TG2 protein and activity were visualized
around the wounded area (Figure 3A). Comparison of TG2
activity in WI-38 monolayers bearing 20 minute old wounds
versus freshly wounded monolayers showed no difference in
crosslink formation, suggesting that the region of intense
enzymatic TG2 activity surrounding the wound was not due to
active export (Figure S1A). In order to gauge how long TG2
protein remains active after wounding, scratches were made 48,
24, 12, and 0 hours before adding the TG2 substrate 5-BP.
Interestingly, TG2 activity could only be detected at the 0 hour
time-point despite the presence of anti-TG2 antibody staining
around the wounded area for all time-points, even the 48 hour
time-point with completely healed wounds (Figure 3B–C).
Furthermore, incubation of the fibroblasts with exogenous
recombinant human TG2 resulted in exclusive co-localization
with the extensive fibronectin ECM network constructed by the
cells, whereas TG2 protein and crosslinking activity around the
wounded area showed only a partial overlap with fibronectin
(Figure 3C–D). Thus, catalytically active TG2 observed after
monolayer wounding may be liberated from lysed cells and/or
extracellular TG2 that was sequestered in an inactive form before
scratching. Propidium iodide nuclear staining of WI-38 cells after
wounding confirmed the presence of lysed cells localized
exclusively around the wound although the stained nuclei did
not always co-localize with TG2 activity (Figure S1B). Scratched
monolayers treated with TG2 irreversible inhibitor 2B completely
blocked TG2 activity, whereas incubation with 2C, an inactive
diastereomer of 2B, was unable to inhibit TG2 activity (Figure 3E).
Small intestinal TG2 is activated following small intestinal
injury with poly(I:C)
Encouraged by the activation and inhibition of TG2 in the
fibroblast wounding model, we evaluated a mouse model of small
intestinal wounding to determine whether TG2 would be activated
following chemically induced tissue damage. Polyinosinic-poly-
cytidylic acid (poly(I:C)) is a double-stranded RNA analogue that
activates the innate immune pattern recognition receptor, toll-like
receptor 3 (TLR3), in the small intestine [26]. Previous work has
shown that activation of TLR3 by poly(I:C) causes human mast
cells to detach from fibronectin in the extracellular matrix [34].
Because TG2 is known to be an integrin-binding adhesion co-
receptor for fibronectin [27,28], we chose this small intestinal
injury model to determine if small intestinal TG2 could be
activated. Mice were given a single intraperitoneal dose of 30 mg/
kg poly(I:C) to induce small intestinal damage. Of this cohort, mice
were either intraperitoneally injected with 100 mg/kg 5-BP after
0 hours and 3 hours and sacrificed at 6 hours or injected with 5-
BP after 6 hours and 9 hours and sacrificed at 11 hours. Control
groups included mice treated with either poly(I:C) and 2 injections
of PBS (poly(I:C)/PBS), PBS and 2 injections of 5-BP (PBS/5-BP),
or PBS and 2 additional injections of PBS (PBS/PBS).
As shown in Figure 4A, poly(I:C) rapidly induced villous
atrophy within 6 hours of injection and tissue damage was
maintained through the 12 hour time-point as reported previously
[26]. Moreover, Western blots of small intestinal tissue homoge-
nates using HRP conjugated streptavidin to detect proteins
covalently labeled with 5-BP showed extensive protein labeling
in the poly(I:C)/5-BP group of mice but only background labeling
in all other groups (Figure 4B). To visualize the tissue localization
of 5-BP labeled proteins, OCT tissue sections were stained with
fluorescently labeled streptavidin and viewed using fluorescence
microscopy. All control tissue sections showed background levels
of staining while three out four poly(I:C)/5-BP mice showed
marked increases in TG2 activity (Figure 4C, Figure S2).
Moreover, the 5-BP signal in the latter sections overlapped with
anti-TG2 staining, suggesting that the 5-BP labeling was due to
TG2 enzymatic activity (Figure 4D).
Discussion
Transglutaminase 2 mediated transamidation and deamidation
reactions are thought to contribute to the pathogenesis of a wide
range of diseases [17]. However, because TG2 is also believed to
contribute to many important biological processes, it is thought
that pharmacological inhibition of TG2 may have undesirable side
effects. This hypothesis assumes that a fraction of TG2 is
constitutively active in vivo, and that this activity is important
under normal physiological conditions. Yet, data supporting a
physiological role for the catalytic activity of TG2 is scarce. In fact,
the normal development and normal phenotype of TG2 knockout
mice [35,36], together with the lack of toxicity observed in mice
dosed chronically with dihydroisoxazole inhibitors [18,20,37]
suggest that TG2 activity is unnecessary for survival in a stress-
free environment.
An intrinsic difficulty in studying the biology of TG2 enzyme
activity is its localization in multiple cellular compartments and
association with a variety of protein binding partners. Earlier
reports [24,25] suggest that cytosolic TG2 in healthy cultured cells
is catalytically inactive due to the low calcium, high GTP
environment inside the cell. In contrast, the enzymatic activity
of extracellular TG2 is unclear because, although calcium is
abundant, the TG2 is associated with extracellular matrix proteins
such as fibronectin and integrins [27,38]. We therefore sought to
investigate the catalytic activity of extracellular TG2 under normal
and stressed conditions.
Although TG2 protein and calcium-activated TG2 activity co-
localize with fibronectin-bound TG2 in the small intestine (see
Figure 2B–C), our data (see Figures 2B, 4C, S2 and S3E) suggests
that extracellular TG2 in this organ is typically inactive even
though the concentrations of calcium and GTP in the extracellular
environment should favor TG2 activity. We therefore sought to
verify that TG2 stabilizes and remodels the ECM following tissue
damage [1,39]. Consistent with this hypothesis, abundant TG2
activity was detected around a wound in a scratched fibroblast
monolayer while almost no TG2 activity was detected in uninjured
regions of the monolayer despite the presence of cell surface TG2
Activation of Transglutaminase
PLoS ONE | www.plosone.org 4 March 2008 | Volume 3 | Issue 3 | e1861Figure 3. Activation of TG2 in a fibroblast wounding assay. (A) TG2 activity (red) and TG2 protein (blue) were visualized in situ after scratching
a confluent WI-38 monolayer with a small pipette tip. WI-38 nuclei were visualized with propidium iodide (PI) to illustrate the relative size of a typical
scratch compared to an individual cell. No significant TG2 activity was detected in unscratched regions of the WI-38 monolayer. (B) TG2 is
enzymatically inactivated within 12 hours of WI-38 wounding despite the persistence of anti-TG2 protein staining. WI-38 monolayers were scratched
48, 12, and 0 hours before adding 5-BP to test for TG2 activity (red). The cells were co-stained for fibronectin (green) and TG2 (blue). (1006) (C) Triple
staining of scratched WI-38 monolayers for fibronectin (green), TG2 (blue), and TG2 activity (red) revealed nearly perfect overlap between TG2 and
TG2 activity (purple) but only partial overlap with fibronectin (white). This partial overlap of TG2 protein (blue) and fibronectin (green) was not
observed 12 hours after wounding. (4006) (D) Addition of exogenous recombinant human TG2 to the monolayers resulted in TG2 deposition onto
the WI-38 assembled fibronectin matrix (colocalization in yellow). (E) TG2 inhibitor 2B was able to block in situ TG2 activity, whereas the control
compound 2C could not block activity.
doi:10.1371/journal.pone.0001861.g003
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PLoS ONE | www.plosone.org 5 March 2008 | Volume 3 | Issue 3 | e1861Figure 4. Small intestinal injury by poly(I:C) induces activation of normally latent small intestinal TG2. Mice were injected with 30 mg/
kg poly(I:C) at t=0 to induce injury to the small intestine while controls received vehicle (PBS). Mice were then injected with either 100 mg/kg 5-BP or
PBS after 0 hours and 3 hours then sacrificed at 6 hours (labeled ‘‘6 hours’’) or injected after 6 hours and 9 hours then sacrificed at 11 hours (labeled
‘‘11 hours’’). One mouse became sick and needed to be sacrificed after 9.5 hours (labeled ‘‘9.5 hours’’). (A) H&E staining of small intestinal tissues
revealed obvious villous atrophy at both the 6 hour and 11 hour time-points following poly(I:C) injection. (B) Small intestinal tissue lysates were
Western blotted using HRP-conjugated streptavidin to detect 5-BP labeled proteins. All mice receiving the combination of poly(I:C) and 5-BP showed
extensive protein labeling while all controls showed background labeling. (C) Immunofluorescent staining of OCT intestinal tissue sections with
fluorescent streptavidin revealed the localization of 5-BP labeled proteins in the poly(I:C)/5-BP mice but showed no labeling in any of the control
tissues. (D) Fluorescent streptavidin staining of intestinal tissue from poly(I:C)/5-BP treated mice showed co-localization with anti-TG2 antibody
staining suggesting that the 5-BP labeling was due to TG2 activity.
doi:10.1371/journal.pone.0001861.g004
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20 minutes prior to the addition of the 5-BP TG2 substrate
showed the same activity profile as fibroblasts immediately
wounded in the presence of 5-BP (Figure S1A), this pool of
activated TG2 did not appear to be secreted by the wounded
fibroblasts. This hypothesis is also supported by the presence of
propidium iodide positive cells around the wounded area, which is
indicative of loss of plasma membrane integrity during the
wounding process (Figure S1B). Therefore, at least a portion of
the TG2 activity was caused by the loss of calcium homeostasis in
lysed cells. Co-staining with fibronectin indicated only a partial
overlap between TG2 protein (or TG2 activity) and fibronectin
(see Figures 3B–C). A fraction of the non-fibronectin associated
activity presumably came from the activation of TG2 inside
partially lysed cells that had lost calcium homeostasis due to
plasma membrane disruption but were still able to retain their
intracellular protein content. Overall, our data indicates that
intracellular TG2 is rapidly activated once a cell loses plasma
membrane integrity. Thus, experiments attempting to measure the
activity of extracellular TG2 in cell culture require a conditioned
media control to account for TG2 released into the media due to
cell lysis during the experiment.
Based upon the activation of TG2 in the fibroblast wounding
model, we attempted to demonstrate injury-induced TG2
activation in vivo. Our initial experiments focused on a methotrex-
ate (MTX) model of small intestinal injury [40,41]. Although a
previous report had shown an increase in TG2 protein expression
in the small intestines of MTX-dosed rats [42], we were unable to
observe significant changes in TG2 expression in conjunction with
dose- or time-dependent damage to the small intestinal mucosa of
mice treated with MTX (Figures S3, S4). Moreover, attempts to
detect the in vivo enzymatic activation of the normally inactive
small intestinal TG2 following MTX induced injury were
unsuccessful (Figure S3). In contrast, the double-stranded RNA
analogue poly(I:C) resulted in extensive TG2 activation in the
mouse small intestine (Figure 4). The latter result is consistent with
an earlier observation that poly(I:C)-mediated activation of TLR3
leads to decreased cell adhesion to the ECM protein fibronectin
[34]. It is unclear whether the differences in TG2 activation
observed using MTX or poly(I:C) to induce small intestinal injury
are model specific or a result of differences in the time-points
taken. In the MTX model, the first group of mice was sacrificed on
day 5 whereas in the acute poly(I:C) injury model all mice were
sacrificed within 11 hours of injection. It is possible that TG2 was
activated at some point during the first four days following MTX
administration, and subsequently inactivated. For example, the
WI-38 fibroblast injury model showed that TG2 activity was
inactivated within 12 hours after the wound was inflicted,
notwithstanding the continued presence of the protein
(Figures 3B–C). Therefore, activation of the large but catalytically
inactive pool of TG2 in the small intestine following tissue injury
appears to be a relatively rapid and short-lived phenomenon.
Toll-like receptors (TLR) are innate immune system receptors
that bind to common pathogenic components, such as lipopoly-
saccharide, cell wall components, or double-stranded RNA,
resulting in an outside-in cellular signaling cascade that ultimately
causes activation of the immune system. Our data indicates that
one potential consequence of the outside-in signal caused by
stimulation of a TLR or related receptor may be the generation of
an inside-out signal triggering enzymatic activation of extracellular
TG2. Recent data indicates that TLR2 and TLR4 expression are
upregulated in the intestinal mucosa of treated and untreated
celiac sprue patients [43]. Combined with our findings, we
speculate that the presence of elevated toll-like receptors in celiac
mucosa leads to a constitutively higher level of extracellular TG2
activity. Once activated, TG2 selectively deamidates gluten
peptides making them potent antigens and resulting in stimulation
of HLA-DQ2 restricted CD4
+ T cells residing in the intestinal
lamina propria [15].
In summary, our data demonstrates that intracellular as well as
extracellular TG2 is catalytically inactive under normal physio-
logical conditions, and that physical or certain types of chemical
injury can lead to rapid enzymatic activation. Parenthetically we
note that our recent X-ray crystal structure of human TG2 bound
to an active site inhibitor has revealed that the protein undergoes a
large (.100 A) conformation change upon activation into its
catalytically active form [44]. Whereas intracellular conditions
(low Ca
+2, high GTP) favor the inactive conformation, we
speculate that cell surface TG2 remains inactive due to its
association with integrins and its ability to form ternary complexes
with cell surface integrin and ECM fibronectin. Physical injury
results in release of intracellular TG2, which rapidly assumes an
active conformation as a result of GTP dissociation and Ca
+2
binding. If so, then our data suggests that chemical injury, such as
the stimulation of toll-like receptors, triggers release of extracel-
lular TG2 from cell surface integrin and concomitant enzyme
activation. Thus, nature appears to have evolved an elaborate
mechanism for the post-translational regulation of enzymatic
activity of this multifunctional protein in response to diverse
physical and chemical stress signals. On one hand, the mammalian
body needs a relatively non-specific crosslinking enzyme in
virtually every organ in order to facilitate rapid tissue growth
and healing. On the other hand, given the extreme stability of an
isopeptide linkage, uncontrolled TG2 activity would likely lead to
excessive scar tissue formation as well as the formation of neo-
epitopes that could trigger an autoimmune response, as in the case
of celiac sprue. Thus, the catalytic activity of TG2 must be
activated rapidly when needed, and inactivated soon after its task
is complete. Perturbation of this delicate balance may be the basis
of a variety of seemingly unrelated diseases.
Methods
Cell culture and antibodies
WI-38 fibroblasts were grown in minimum essential media
(Gibco, 11095) containing L-glutamine, Earle’s salts, non-essential
amino acids (Gibco, 11140), sodium pyruvate (Gibco, 11360), 10%
fetal bovine serum (FBS) (Atlanta Biologicals), and 100 U/ml
penicillin+100 mg/ml streptomycin (Gibco, 15140). MDA-MB-
231 cells were grown in RPMI-1640 with L-glutamine (Gibco,
11875), 10% FBS (Atlanta Biologicals), and 100 U/ml penicilli-
n+100 ug/ml streptomycin (PS). Cells were typically grown to 80–
90% confluency before treating with trypsin-EDTA (Gibco,
15400) and splitting. All cells were grown in a humidified
incubator at 37uC, 5% CO2. The antibodies used were a rabbit
polyclonal anti-TG2 antibody (Lab Vision Corp., RB-060),
CUB7402/TG100 mouse anti-TG2 antibody mix (Lab Vision
Corp., MS-300), rabbit anti-fibronectin (Sigma, F3648), Alexa
fluor 488 goat anti-rabbit antibody (Invitrogen, A-11008), Alexa
fluor 568 goat anti-mouse antibody (Invitrogen, A-11004), Alexa
fluor 647 labeled streptavidin (Invitrogen, S21374), and Alexa
fluor 514 labeled streptavidin (Invitrogen).
Transglutaminase inhibitor synthesis
The TG2 inhibitors used in this study are summarized in
Figure 1A. 3-bromo-4,5-dihydroisoxazole inhibitors were synthe-
sized according to previously published procedures [18,19]. New
TG2 inhibitor (compound 1) was prepared as follows.
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(1-(dimethylamino) naphthalene-5-sulfonamido)-3-(1H-
indol-3-yl)propanamide (1) 59.6 mg (0.111 mmol) N-dansyl-
L-tryptophan was dissolved in 1.11 mL neat DMF (0.1M), and
placed in a water/ice bath. 21.8 mg of 7-amino-3-bromo,4-,5-
dihydroisoxazole (0.122 mmol, 1.1 equiv) were added to the
reaction mixture followed by 16.5 mg (0.122 mmol, 1.1 equiv) of
hydroxybenzotriazole hydrate, and 23.4 mg of EDCI (0.122 mmol,
1.1 equiv). The reaction was allowed to run for 12 hrs, was followed
by an aqueous workup with 1M phosphate buffer at pH 3,
extraction with EtOAc (565ml), drying over sodium sulfate,
concentration under reduced pressure and purification by prep.
TLC in 4:1 dichloromethane: acetone (yield 71.8%).
1HN M R
(500MHz, CDCl3): d 1.24–1.27 (dd, 1H, J=7.0,7.0), 1.98–2.00 (m,
1H, J=5.0), 2.022 (s, 1H), 2.22 (s, 1H), 2.65–2.70 (dd, 1H, J=8.0,
17.5), 2.91–2.93 (dd, 1H, J=0.5, 17.5), 2.96–3.06 (m, 3H), 3.10–
3.16 (ddd, 1H, J=5.0, 6.0, 14.0), 3.90–3.94 (ddd, 1H, J=6.0, 7.5,
14.0), 4.086–4.128 (ddd, 1H, J=7.0, 14.0, 7.0), 4.39–4.45 (m, 1H),
6.18–6.19 (d, 1H, J=7.5), 6.67–6.69 (dd, 1H, J=5.5, 5.5), 6.91–
6.92(d,1H,J=2.5),6.93–6.97(ddd,1H,J=1.0,7.0,8.0),7.06–7.10
(ddd, 1H, J=1.0, 7.0, 8.0) 7.24–7.27 (m, 2H), 7.27–7.29 (ddd, 1H,
J=1.0, 2.0, 6.0), 7.43–7.57 (ddd, 2H, J=6.5, 1.5, 56.0), 8.07–8.09
(dd, 1H, J=1.0, 7.0), 8.15–8.17 (ddd, 1H, J=0.5, 0.5, 8.5), 8.45–




SDS PAGE and Western Blotting
Samples were diluted 1:1 with 26 Laemmli sample buffer
containing b-mercaptoethanol, and boiled for 10 mins. Samples
were applied to 4–12% or 4–15% SDS PAGE gels (Bio-Rad,
Invitrogen). For Western blotting, proteins were transferred onto a
nitrocellulose membrane at 80 volts for 1 hour in transfer buffer
(2.42 g Tris, 11.2 g glycine to 800 ml plus 200 ml methanol).
Membranes were blocked with 2% non-fat dry milk in PBS
(blocking buffer) for 30 minutes at room temp. Horseradish
peroxidase conjugated neutravidin (Invitrogen) was incubated with
the nitrocellulose membrane overnight at 4uC in blocking buffer.
The substrate ELC plus (GE Life Sciences) was used to visualize
staining according to the manufacturers protocol. The membrane
was scanned using a Typhoon fluorescence imager (GE Life
Sciences).
Cell culture inhibition experiments
To quantify TG2 inhibition in cultured cells, cells (MDA-MB-
231 and WI-38) were grown to near confluence. Dihydroisoxazole
inhibitor 1 was diluted to its indicated concentration in culture
media, and vehicle (0.5% DMSO) was added to the media of
control cells. Cells were incubated with the inhibitor for the
indicated amount of time at 37uC, 5% CO2 before being washed
with PBS (pre-warmed to 37uC) for 15 mins in the incubator to
allow any free inhibitor to diffuse out from cells. MDA-MB-231
cells were detached with 10 mM EDTA in PBS at 37uC to avoid
proteolysis of extracellular TG2. However, trypsin-EDTA detach-
ment was necessary for the ECM-rich WI-38 cells. Cell pellets
were resuspended to approximately 7*10
6 cells/ml in 50 mM
mannitol, 2 mM tris, 1 mM EDTA (MTE) buffer. Cells were lysed
by sonicating 56for 8 sec. each using a microtip sonicator. The
cell lysate was divided into four 80 ml aliquots and either 1%
DMSO, 1% DMSO+5 mM CaCl2, 1% DMSO+100 uM 1,o r
1% DMSO+100 uM 1+5 mM CaCl2 was added to the aliquots
and allowed to incubate for 30 mins at room temp. Putrescine
incorporation in a calcium-rich buffer was then used to measure
the amount of TG2 activity in the lysates.
In vivo inhibition experiments
Dihydroisoxazole inhibitors were dissolved in solutions ranging
from 50%–100% DMSO in PBS. Controls received vehicle only.
For experiments in mice, inhibitor was injected either intraper-
itoneally (IP) or retro-orbitally (IV) at 100 ml per 20 g mouse
weight. Mice were sacrificed using CO2 inhalation one hr after
injection followed by harvesting of the small intestine and liver.
The liver was immediately frozen in liquid nitrogen. In some
experiments, the small intestine lumen was rinsed with PBS using a
needle and syringe. The small intestine was cut longitudinally, and
the mucosa was scraped using microscope slides. Intestinal mucosa
was wrapped in parafilm and frozen on dry ice. In some
experiments, blood was collected by tail bleeding and immediately
frozen in liquid nitrogen. Transglutaminase 2 knockout mice and
wild-type controls were described previously [45].
Intestinal tissue was homogenized to 20% wt/wt and livers to
10% wt/wt in 50 mM mannitol, 2 mM Tris HCl, 1 mM EDTA,
pH 7.4 (MTE) solution using a Wheaton glass dounce homoge-
nizer. Samples were sonicated 26 for 8 sec. with a microtip
sonicator. The resulting lysate was used in the putrescine
incorporation assay.
Putrescine incorporation assay
Incorporation of putrescine into N,N-dimethyl casein was
measured as described previously [18]. The dimethyl casein
substrate buffer contained 10 mM [1,4-
14C] putrescine and 50 mM
unlabeled putrescine, and the reaction was initiated by adding 1
volume of lysate to 4 volumes of calcium-rich substrate buffer. For
cell culture inhibition experiments, putrescine incorporation was
measured only at 0 and 10 minutes since the presence of
dihydroisoxazole inhibitors in some of the samples led to a time-
dependent inhibition of TG2 activity that was more visible at later
timepoints.
Rat small intestinal perfusion
Rat intestinal perfusion experiments were performed as described
previously [46]. Vehicle (1% N-lauroyl sarcosine for 2A perfusions
and 0.9% NaCl for 5-biotinamidopentylamine (5-BP) perfusions)
was perfused through 20 cm of the rat jejunum for 15 mins at a flow
rate of 24 ml/hr. Then, the middle 10 cm section of the pre-
perfused jejunum was perfused with the compound of interest
(2.4 mM 2A or 500 mM 5-BP) for 15–20 minutes at 24 ml/hr. The
animal was sacrificed and tissue sections from the control and
compound perfused sections were frozen in OCT on dry ice for
subsequent tissue sectioning experiments.
In situ TG2 activity assay and tissue staining
In situ TG2 activity was measured in rodent tissue sections
according to a previously published protocol [22] with the
following modifications. The 5-biotinamidopentylamine (Pierce,
21345) substrate was incubated with the tissue section for 1 hr at
room temp. instead of 2 hours and, in some experiments, the
concentration of 5-BP was titrated down to 5 mM. Alexa fluor 647
conjugated streptavidin (1:100 in blocking buffer) was used to
detect 5-BP crosslinked to tissue sections, and Alexa fluor 488 anti-
rabbit IgG and Alexa fluor 568 anti-mouse IgG secondary
antibodies (1:1000 in blocking buffer) were used to detect primary
antibody staining. The slides were mounted using VECTA-
SHIELD mounting medium containing DAPI (Vector Labs). It
should be noted that 5-BP was incubated with the tissue section in
a buffer containing 5 mM CaCl2. Thus, the in situ TG2 activity
signal is not necessarily indicative of true in vivo TG2 activity as
demonstrated in the Results section.
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The WI-38 fibroblast scratch model was based upon a
modification of a previously published protocol [33]. WI-38
fibroblasts were plated in an 8-well chamber glass slide at 10
5
cells/well and grown for 7–10 days with a media change every
2 days. Small scratches were made in the monolayer with a 0.1–
10 ml pipette tip, and the cells were incubated with 100–500 mM
5-BP for 30–60 mins at 37uC. The cells were washed 36with PBS
then fixed with 220uC methanol for 10 mins. The cells were
washed with PBS 26for 5 mins, blocked with 1% BSA in PBS for
5 mins at room temp, and then washed 26using PBS. Alexa fluor
647 labeled streptavidin was diluted 1:500 in blocking buffer and
incubated with the cells for 30–60 mins at room temp. The cells
were washed 46 with PBS and 300 ml PBS was added onto the
cells before viewing with a confocal laser scanning microscope. For
propidium iodide (PI) staining, a 1 mg/ml stock solution of PI in
PBS was diluted 1:1000 in PBS and incubated at room temp with
cells for 5 mins. Cells were washed 36 and visualized using
microscopy.
To determine whether the released TG2 was being actively
exported or simply leaking out, the rate of extracellular TG2
accumulation was measured. Scratches were made to monolayers,
and the cells were incubated at 37uC for 20 mins in normal media.
Then, 500 mM 5-BP was added to these previously scratched wells
and also to unscratched wells, which were then immediately
scratched. After the indicated time-points, the 5-BP was washed off
36with PBS. The fixation and staining protocol was the same as
described above.
For propidium iodide staining of live cells, stock PI was diluted
1:1000 in PBS and incubated with live cells for 5 mins at room
temp. The monolayer was washed 36with PBS and the cells were
fixed with 4% paraformaldehyde for 10 mins at room temp. The
cells were washed 36with PBS and viewed under the microscope.
For TG2 inhibitor experiments, the inhibitors were diluted into
culture medium at 100 mM and incubated with the cells for
20 mins after scratching. Then, 100 mM 5-BP was added to wells
and co-incubated with the inhibitors for 30 mins before fixing and
staining as described above.
Poly(I:C) induced small intestinal damage in mice
C57BL/6 mice (8 weeks old) were IP injected with 30 mg/kg
poly(I:C) (Sigma, P1530) dissolved in PBS to injure the small
intestine as described previously [26]. Controls were given vehicle
(PBS only). 5-BP was dissolved to 27.8 mg/ml in water and diluted
to 25 mg/ml using 106 PBS. Mice were IP injected twice with
either 100 mg/kg 5-BP or PBS at three hr intervals. For mice
sacrificed after 6 hrs, 5-BP or PBS was injected at 0 and 3 hrs. For
mice sacrificed after 11 hrs (or 9.5 hrs for one mouse), 5-BP or
PBS was injected at 6 and 9 hrs. Therefore, 5-BP/PBS was
injected between 5–6 and 2–3 hours before sacrifice for both the
6 hour and 11 hour timepoints. The lumens of isolated small
intestines were rinsed with PBS using a needle and syringe, and
small pieces of tissue were formalin-fixed for hematoxylin and
eosin (H&E) staining or frozen in OCT for subsequent
immunofluorescence staining. The intestine was cut longitudinally,
and the intestinal mucosa was scraped using microscope slides,
wrapped in parafilm, and frozen on dry ice. Upon thawing, tissue
was homogenized with a Wheaton dounce homogenizer in
50 mM mannitol, 2 mM tris, 10 mM EDTA, pH=7.4, sonicated
2X, and diluted in Laemmli sample buffer for SDS PAGE and
Western blotting. HRP conjugated neutravidin (Invitrogen, A-
2664) and ECL plus substrate (GE Biosciences) were used to
visualize biotinylated proteins. The four groups of mice (poly(I:C)/
5-BP, poly(I:C)/PBS, PBS/5-BP, PBS/PBS) were analyzed in
duplicate using one male and one female mouse.
Methotrexate induced small intestinal damage in mice
Methotrexate (Sigma, 06563) was dissolved in 33% 0.1 M
NaOH+66% PBS with a small amount of 2 M NaOH necessary
to completely dissolve the compound to 12.5 mg/ml. Mice were
orally gavaged with 50 mg/kg methotrexate or PBS daily for the
indicated number of days. Animal body weight was monitored
daily until the time of sacrifice. Animals were sacrificed using CO2
inhalation, and small intestinal tissue was collected, rinsed with
PBS using a needle and syringe, and cut longitudinally. Intestinal
mucosa was scraped using microscope slides, wrapped in parafilm,
and frozen on dry ice. Small cross-sectional tissue pieces were
either fixed in formalin or frozen in OCT freezing medium. C57/
BL6J mice were used in the first two MTX experiments and FVB
mice were used in the FC/5-BP MTX experiments.
Fluorescein cadaverine (FC) (Fisher, PR-P1911) was dissolved in
0.5 M NaOH to 69 mM and further diluted to 14 mM in PBS.
The FC concentration was calculated from its absorbance at
495 nm, using 80,500 cm
21M
21 as the extinction coefficient.
Mice were injected IP with three 30 mg/kg FC doses at 29, 17,
and 5 hrs before sacrifice. 5-BP was dissolved to 50 mM in water
and diluted to 45 mM using 106PBS. Mice were IP injected with
two 120 mg/kg 5-BP doses at 17 and 5 hrs before sacrifice.
Control mice were injected with an equivalent volume of PBS.
Pharmacokinetic data using a 5 mg/kg dose of FC gave a serum
half-life of around 25 mins and peak serum concentration of
15 mM (data not shown). Two mice were injected with 150 mg/
kg monodansylcadaverine, a widely used amine substrate of TG2,
but it proved to be toxic, leading to animal death within 20 mins.
Supporting Information
Figure S1 Enzymatically active TG2 is not exported from WI-
38 cells near the wound. (A) Small puncture wounds were made to
WI-38 fibroblast monolayers either 20 minutes prior to the
addition of 5-BP or in the presence of 5-BP. The reaction was
allowed to proceed for the indicated time before the monolayers
were washed free of 5-BP and fixed/permeabilized with methanol.
The localization and intensity of TG2 activity around the
20 minute old wound and fresh wound were nearly identical
indicating that the TG2 activity was not due to TG2 actively
exported by cells proximal to the wound. (B) Co-staining of
wounded WI-38 monolayers for TG2 activity (red) and propidium
iodide (PI, a dead cell nuclear stain, blue) showed significant cell
lysis around the wounded area, although the TG2 activity staining
and PI staining did not always perfectly overlap (co-localization is
pink).
Found at: doi:10.1371/journal.pone.0001861.s001 (6.96 MB TIF)
Figure S2 Small intestinal injury by poly(I:C) induces activation
of normally latent small intestinal TG2. Mouse small intestinal
OCT sections from poly(I:C) treated mice and controls were
stained with Alexa fluor 514 labeled streptavidin. Representative
fluorescent microscopy images from each poly(I:C)/5-BP treated
mouse are shown. Images from two control mice are also displayed
to show background staining levels.
Found at: doi:10.1371/journal.pone.0001861.s002 (2.91 MB TIF)
Figure S3 Methotrexate-induced small intestinal damage does
not result in up-regulation or activation of TG2. (A) Mice were
perorally dosed daily with between 1–5 doses of MTX as indicated
on the graph. On day 7, all mice were sacrificed. Although H&E
staining of the tissue revealed dose-dependent damage, there was
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putrescine incorporation assay. (B) Mice were given either 3
peroral doses of MTX or vehicle (PBS) daily between days 0–2.
Body weight was monitored over the duration of the experiment
and plotted as percent body weight based upon day 0 weights.
____(green) Mice given FC; ____(red) Mice given 5-BP;
____(blue) Mice given vehicle (PBS) (C) Formalin fixed small
intestinal tissue sections from vehicle treated and MTX treated
mice sacrificed on days 5, 8, and 9 were stained with H&E to
verify the small intestinal damage caused by MTX. (100X) (D)
Small intestinal tissue lysate from vehicle treated and FC treated
mice were separated by SDS PAGE and subsequently scanned for
FC fluorescence. Although free FC was still present in the tissues,
all proteins labeled with FC were also labeled in the lysate from FC
injected TG2 knockout mice. Labels indicate the dosing schemes,
and TG2 knockout and wild-type mice injected with FC are
denoted KO and WT, respectively. (E) In situ TG2 activity could
be detected in vehicle treated mouse OCT tissue sections by
incubating the section with 5 mM 5-BP in a calcium containing
buffer at room temperature for 1 hour. However, no in situ
staining representative of in vivo TG2 activity could be detected in
two MTX treated mice dosed with 2 intraperitoneal injections of
120 mg/kg 5-BP.
Found at: doi:10.1371/journal.pone.0001861.s003 (6.73 MB TIF)
Figure S4 Small intestinal TG2 protein content is not
upregulated during methotrexate-induced small intestinal wound-
ing. Mice were perorally dosed on two consecutive days with
methotrexate to cause small intestinal damage. Two mice were
sacrificed each day over the course of ten days, and their small
intestinal mucosa was harvested. Putrescine incorporation was
used to quantify the amount of TG2 protein in the intestine. No
significant changes in protein expression levels were observed
despite intestinal damage.
Found at: doi:10.1371/journal.pone.0001861.s004 (0.74 MB TIF)
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